Mondego Bio Reveals PTPN2 Inhibitor ZE00-0388 to Enter Clinical Trials by 2026 Mondego Bio has announced the selection of ZE00-0388 as their lead clinical candidate for a Phase 1 study commencing in H1 2026, focusing on PTPN2 inhibition.

Mondego Bio Reveals PTPN2 Inhibitor ZE00-0388 to Enter Clinical Trials by 2026 #Portugal #Mondego_Bio #Cantanhede #ZE00-0388 #PTPN2_Inhibitor

ChemDiv and Mondego Bio Strengthen Partnership for Immuno-Oncology Advancements in PTPN2 Targeting ChemDiv has extended its partnership with Mondego Bio to enhance the development of innovative immuno-oncology therapies targeting PTPN2.

ChemDiv and Mondego Bio Strengthen Partnership for Immuno-Oncology Advancements in PTPN2 Targeting #USA #San_Diego #Mondego_Bio #ChemDiv #PTPN2

Mondego Bio: A New Frontier in Immuno-Oncology Funding Success Mondego Bio has emerged from Expert Systems Inc. with Series A funding aimed at combating immune resistance in solid tumors, revolutionizing cancer treatments.

Mondego Bio: A New Frontier in Immuno-Oncology Funding Success #Portugal #Expert_Systems #Mondego_Bio #PTPN2_inhibitors #Cantanhede

Biovance Capital Secures Series A Funding for Mondego Bio's Innovative Cancer Treatments Biovance Capital has led a significant Series A funding round for Mondego Bio, a startup focused on pioneering cancer therapies. Their work on PTPN2 inhibitors shows promise for improving immunotherapy outcomes.

Biovance Capital Secures Series A Funding for Mondego Bio's Innovative Cancer Treatments #Portugal #Lisbon #Biovance_Capital #Mondego_Bio #PTPN2_inhibitors